Most Clicked DiabetesPro SmartBrief Stories

1. Experts question accuracy of blood glucose meters in low glycemic range

DiabetesPro SmartBrief | Jul 24, 2015

An assessment found considerable differences in the performance of blood glucose meters in the low glycemic range, which could explain why BG measurement data is not accepted by the FDA as evidence for the efficacy of antidiabetic drugs for reducing hypoglycemia, researchers reported in Diabetes Care. They questioned whether these devices can be used in clinical trials to evaluate hypoglycemia risk. (07/22)

2. Few obese people return to normal weight, study says

DiabetesPro SmartBrief | Jul 20, 2015

U.K. research in the American Journal of Public Health found only 1 in 210 obese men and 1 in 124 obese women are likely to return to their normal weight and the odds are even worse for those who are severely obese. Many people were able to reduce their body weight by 5%, but 78% gained it back within five years, researchers said. (07/16)

3. Daily soda consumption tied to increased type 2 diabetes risk

DiabetesPro SmartBrief | Jul 22, 2015

A daily serving of sugar-sweetened drinks increases type 2 diabetes risk by 13% over a decade, even after accounting for weight, according to a review in BMJ. Lead author Fumiaki Imamura said that the regular consumption of refined sugar can raise insulin resistance even in normal-weight people. HealthDay News (07/21)

4. Similar CVD risk with sulfonylureas or insulin plus metformin

DiabetesPro SmartBrief | Jul 20, 2015

Researchers found a similar risk of myocardial infarction or stroke among type 2 diabetes patients who were treated with sulfonylureas or insulin in combination with metformin. The findings were published in Diabetes, Obesity and Metabolism. (07/17)

5. Type 1 diabetes patients see benefit from psoriasis drug

DiabetesPro SmartBrief | Jul 23, 2015

Patients with newly diagnosed type 1 diabetes had a lower decline in C-peptide secretion over two years of follow-up after taking alefacept, a drug for psoriasis, for two 12-week courses, compared with those on placebo, according to a study in the Journal of Clinical Investigation. Researchers also found that C-peptide production didn't decline among nine of 30 patients who were evaluated for C-peptide function and the preservation of C-peptide lasted as long as 15 months after stopping treatment. (07/22)

6. Hospitals recognize importance of managing inpatient diabetes

DiabetesPro SmartBrief | Jul 20, 2015

Hospitals across the U.S. acknowledge that managing inpatient diabetes is important to the delivery of quality patient care. Challenges include which hospital team is responsible for diabetes patient management, the risk of hyperglycemia, medication interference, nutrition, as well as quality improvement efforts and discharge planning. Endocrine Today magazine (07/2015)

7. Diabetic neuropathy pain responds to inhaled cannabis, study finds

DiabetesPro SmartBrief | Jul 23, 2015

Patients with diabetic neuropathy showed improvement in pain response scores after inhaled cannabis therapy, and the reduction was dependent on dosage, researchers reported in The Journal of Pain. Researchers from the University of California at San Diego said data from the study, which compared three dosages and a placebo, showed cannabis therapy had modest effects on cognition. (07/20)

8. Survey finds many people cannot define gluten

DiabetesPro SmartBrief | Jul 24, 2015

A survey from NSF International found 90% of people had heard about gluten sensitivity or a gluten-free diet but 54% could not correctly define the term. Some common misunderstandings about gluten are that wheat-free products are gluten-free and that all grains contain gluten. (07/21)

9. Many diabetes patients don't get recommended vaccines

DiabetesPro SmartBrief | Jul 21, 2015

Researchers found extensive nonadherence to national guidelines for hepatitis B, influenza and 23-valent pneumococcal polysaccharide vaccines among diabetes patients, who are considered to be at risk for infection and infectious disease complications. The findings were published in the journal Clinical Diabetes. (07/20)

10. Glitazone drugs may reduce Parkinson's risk, study says

DiabetesPro SmartBrief | Jul 22, 2015

A study in PLoS Medicine found patients with diabetes who took glitazones between 1999 and 2013 had a 28% lower risk of Parkinson's disease than those who didn't take the drugs. The study also showed that patients currently taking the drugs had a 41% lower Parkinson's risk. HealthDay News (07/21)

Sign up for DiabetesPro SmartBrief

Designed specifically for health care professionals, DiabetesPro SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news, trends, and technology updates that matter most to health care professionals. Learn more